ImmunityBio, Inc.

NASDAQ:IBRX

Biotechnology

Healthcare
$6.70 +2.58%

+$0.18 today

Market cap
$7.13B
Beta
0.10
P/E (TTM)
-8.6
EPS (TTM)
-$0.83
52W Low $1.95High $12.43

Volume 15.77M

Average 16.40M

IBRX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

ImmunityBio, Inc.NASDAQ: IBRX

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development growth accelerates

Q3 FY2026 research & development of $68.96M rose 35.9% year over year, ahead of the +33.2% change in trailing-twelve-month research & development. Sequentially, it rose 19.5% from the prior quarter. Over 3 fiscal years it compounded at -5.7% a year.

Context

  • Research & development amounted to 183.5% of revenue in FY2025, down 1106.1 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +35.9% holds above the trailing-twelve-month pace of +33.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$68.96M+19.5% QoQ
Last fiscal yearDec 2025
$207.88M+9.3% YoY
LTMSep 2026
$252.23M+33.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+35.9%——
1 year+9.3%——
3-year CAGR-5.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
207.88M USD
Year-over-year change
+9.3%
4-year CAGR
+1.5%

Research & Development vs competitors

How IBRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +33.2% is the highest of 11, against a peer median of -12.2%.
  • Research & development amounts to 138.2% of revenue for IBRX, versus a peer median of 74.9%.
IBRX Competitors
Research & Development for IBRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRNAModerna, Inc.LTM Sep 2026$2.66B USD-23.6%-1.7%105.3%
BNTXBioNTech SELTM Jun 2026€2.18B EUR-0.6%+9.6%82.6%
VIRVir Biotechnology, Inc.LTM Mar 2026$446.24M USD-15.0%-3.0%681.3%
LEGNLegend Biotech CorporationLTM Sep 2026$378.58M USD-9.4%+7.3%27.9%
IMCRImmunocore Holdings plcLTM Mar 2026$259.11M USD+17.2%+34.4%67.2%
IBRXImmunityBio, Inc.LTM Sep 2026$252.23M USD+33.2%-5.7%138.2%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$241.88M USD-19.7%+0.6%63.8%
IMTXImmatics N.V.LTM Mar 2026€201.11M EUR+27.4%+19.9%539.2%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$129.09M USD-32.1%-16.3%—
NKTXNkarta, Inc.LTM Mar 2026$88.91M USD-7.1%-0.2%—
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$10.18M USD-92.4%-48.4%44.0%
Peer median (excluding IBRX) —-12.2%+0.2%74.9%

Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue934K240K622K14.75M113.29M
Cost of Revenue0000753K
Gross Profit934K240K622K14.75M112.54M
Gross Margin100.0%100.0%100.0%100.0%99.3%
Research & Development195.96M248.15M232.37M190.14M207.88M
Selling, General & Admin135.26M102.71M129.62M168.78M147.18M
Operating Expenses331.21M351.54M362.87M358.93M368.56M
Depreciation & Amortization14.24M18.26M18.51M17.55M15.53M
EBITDA(320.75M)(351.88M)(478.66M)(264.43M)(223.56M)
EBITDA Margin-34341.8%-146617.1%-76955.5%-1793.4%-197.3%
Operating Income(330.28M)(351.3M)(362.25M)(344.18M)(256.03M)
Operating Margin-35361.9%-146374.2%-58239.5%-2334.2%-226.0%
Interest Income836K2.71M863K2.4M6.7M
Interest Expense14.85M47.15M86.72M131.66M112.53M
Other Income / Expenses(19.56M)(65.99M)(221.64M)(69.46M)(95.58M)
Income Before Tax(349.84M)(417.29M)(583.89M)(413.65M)(351.61M)
Pre-Tax Margin-37456.0%-173869.2%-93873.3%-2805.3%-310.4%
Income Tax Expense9K34K(40K)0(135K)
Net Income(346.79M)(416.57M)(583.2M)(413.56M)(351.4M)
Net Margin-37129.6%-173569.6%-93761.4%-2804.8%-310.2%
EPS (Basic)(0.89)(1.04)(1.15)(0.59)(0.38)
EPS (Diluted)(0.89)(1.04)(1.15)(0.62)(0.38)
Weighted Avg Shares389.23M399.9M508.64M697.31M919.86M
Weighted Avg Shares (Diluted)389.23M399.9M508.64M700.44M919.86M

ImmunityBio, Inc.

NASDAQ:IBRX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.